KRON - Kronos Bio Inc Stock Price, Fair Value and News

$5.95

Market Closed as of 07 Nov 2025, 04:00 pm ET

KRON Stock Valuation Analysis

Valuation

Max Portfolio %

KRON Price Action

KRON RSI Chart

KRON Stock Valuation Analysis

Valuation

Max Portfolio %

KRON Valuation

KRON Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

KRON Fundamentals

KRON Revenue

KRON Earnings

KRON Profitability

KRON Investor Care

Revenue & Growth

How Kronos Bio Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

Net sales

Year	Q1	Q2	Q3	Q4
2025	-	-	-	-
2024	7.6M	8.4M	-	9.8M
2023	-	-	-	6.3M

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Kronos Bio Inc

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, a next-generation SYK inhibitor to treat the patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. The company was incorporated in 2017 and is headquartered in San Mateo, California.

CEO	Dr. Norbert W. Bischofberger Ph.D.
WEBSITE	https://kronosbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	104